Literature DB >> 26230056

Cardiovascular implantable electronic device infections: associated risk factors and prevention.

Martin Rohacek1, Larry M Baddour2.   

Abstract

Infections of cardiovascular implantable electric devices (CIED) are a burden on patients and healthcare systems and should be prevented. The most frequent pathogens are coagulase-negative staphylococci and Staphylococcus aureus. The most important risk factors for CIED infections are diabetes mellitus, renal and heart failure, corticosteroid use, oral anticoagulation, fever within 24 hours before the procedure and leucocytosis, implantable cardioverter defibrillator compared with pacemaker, especially in the case of Staphylococcus aureus bacteraemia, lack of antibiotic prophylaxis, and postoperative haematoma and other wound complications. Other important risk factors are history of prior procedures and previous CIED infections, number of leads, use of povidone-iodine compared with chlorhexidine-alcohol, and centres and operators with a low volume of implants. To prevent CIED infections, patients undergoing CIED procedures and appropriate devices should be carefully selected, and interventions should be performed by trained operators. Antibiotic prophylaxis should be administered, and skin antisepsis should be done with chlorhexidine-alcohol. Oral anticoagulation should be continued during CIED procedures in high-risk patients for thromboembolism, instead of bridging with heparin. Early reintervention in cases of haematoma or lead dislodgement should be avoided. The implementation of infection prevention programmes reduces infection rates. More randomised controlled studies are needed to evaluate prevention strategies, especially skin preparation and antibiotic prophylaxis with glycopeptides.

Entities:  

Mesh:

Year:  2015        PMID: 26230056     DOI: 10.4414/smw.2015.14157

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  9 in total

1.  The emergence of Staphylococcus aureus as the primary cause of cardiac device-related infective endocarditis.

Authors:  Erwan Donal; Pierre Tattevin; Jean-Marie Urien; Christophe Camus; Christophe Leclercq; Loren Dejoies; Philippe Mabo; Raphael Martins; Sarrah Boukthir; François Bénézit; Nathalie Behar; Matthieu Revest; Sylvain Bodi; Julien Bila
Journal:  Infection       Date:  2021-06-05       Impact factor: 3.553

Review 2.  [Hypersensitivity reactions to implantable cardiac pacemakers and defibrillators].

Authors:  B Kreft
Journal:  Hautarzt       Date:  2016-05       Impact factor: 0.751

3.  Rate, Time Course, and Predictors of Implantable Cardioverter Defibrillator Infections: An Analysis From the SIMPLE Trial.

Authors:  François Philippon; Gilles E O'Hara; Jean Champagne; Stefan H Hohnloser; Michael Glikson; Jörg Neuzner; Philippe Mabo; Xavier Vinolas; Josef Kautzner; Fredrik Gadler; Noa Lashevsky; Stuart J Connolly; Yan Y Liu; Jeff S Healey
Journal:  CJC Open       Date:  2020-04-25

4.  Postoperative Antibiotic Prophylaxis Following Cardiac Implantable Electronic Device Placement.

Authors:  Galen M Kabulski; Amanda Northup; Barbara S Wiggins
Journal:  J Innov Card Rhythm Manag       Date:  2019-08-15

5.  Pacemaker lead endocarditis with hiccups (Kalayci).

Authors:  Belma Kalaycı; Turgut Karabag; Turgay Erten; Tunahan Akgun
Journal:  Caspian J Intern Med       Date:  2018

6.  Enterococcus durans Cardiac Implantable Electronic Device Lead Infection and Review of Enterococcus durans Endocarditis Cases.

Authors:  Milan Radovanovic; Djordje Jevtic; Michel K Barsoum; Janki Patel; Igor Dumic
Journal:  Medicina (Kaunas)       Date:  2022-02-17       Impact factor: 2.430

7.  The change in nutritional status is related to cardiovascular events in patients with pacemaker implantation: A 4-year follow-up study.

Authors:  Kaijing Wang; Liyou Lian; Chengpu Chen; Meiling Wang; Chen Chen; Xiang Hu
Journal:  Front Nutr       Date:  2022-09-02

8.  Is cardiopulmonary bypass standby still required for laser lead extractions?

Authors:  Lindsay Volk; Nina Verghis; Hirohisa Ikegami; Manabu Takebe; Mark J Russo; Leonard Y Lee; Anthony Lemaire
Journal:  J Cardiothorac Surg       Date:  2022-09-15       Impact factor: 1.522

9.  Preclinical evaluation of efficacy and pharmacokinetics of gentamicin containing extracellular-matrix envelope.

Authors:  M Rizwan Sohail; Zerelda Esquer Garrigos; Claude S Elayi; Kun Xiang; John N Catanzaro
Journal:  Pacing Clin Electrophysiol       Date:  2020-03-05       Impact factor: 1.976

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.